CAPTRUST Financial Advisors
LGND icon

CAPTRUST Financial Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

CAPTRUST Financial Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.97M Buy
29,900
+15,321
+105% +$3.03M 0.01% 700
2025
Q4 		$2.76M Sell
14,579
-430
-3% -$82.6K 0.01% 931
2025
Q3 		$2.66M Sell
15,009
-600
-4% -$89.2K 0.01% 887
2025
Q2 		$1.77M Buy
15,609
+3,767
+32% +$403K ﹤0.01% 1031
2025
Q1 		$1.25M Sell
11,842
-192
-2% -$21.7K ﹤0.01% 1148
2024
Q4 		$1.29M Sell
12,034
-188
-2% -$21.3K ﹤0.01% 1099
2024
Q3 		$1.22M Sell
12,222
-407
-3% -$41K ﹤0.01% 1072
2024
Q2 		$1.06M Buy
12,629
+5,912
+88% +$470K ﹤0.01% 1103
2024
Q1 		$491K Buy
6,717
+402
+6% +$29.6K ﹤0.01% 1491
2023
Q4 		$451K Buy
6,315
+330
+6% +$19.5K ﹤0.01% 1805
2023
Q3 		$359K Buy
+5,985
New +$394K ﹤0.01% 1882
2022
Q3 		– Sell
-1,446
Closed -$80K – 3162
2022
Q2 		$80K Buy
1,446
+16
+1% +$908 ﹤0.01% 2376
2022
Q1 		$100K Sell
1,430
-713
-33% -$51.7K ﹤0.01% 2264
2021
Q4 		$207K Sell
2,143
-276
-11% -$25.5K ﹤0.01% 1614
2021
Q3 		$210K Buy
2,419
+56
+2% +$4.33K ﹤0.01% 1527
2021
Q2 		$193K Sell
2,363
-1
-0% -$83 ﹤0.01% 1548
2021
Q1 		$225K Buy
2,364
+2,175
+1,151% +$206K ﹤0.01% 1390
2020
Q4 		$12K Buy
189
+8
+4% +$456 ﹤0.01% 2484
2020
Q3 		$11K Sell
181
-754
-81% -$51.4K ﹤0.01% 2243
2020
Q2 		$65K Sell
935
-1,681
-64% -$107K ﹤0.01% 1520
2020
Q1 		$111K Buy
+2,616
New +$148K ﹤0.01% 1078
2019
Q4 		– Sell
-596
Closed -$37K – 1450
2019
Q3 		$37K Hold
596
– – ﹤0.01% 1093
2019
Q2 		$42K Buy
596
+64
+12% +$4.71K ﹤0.01% 1036
2019
Q1 		$42K Buy
532
+399
+300% +$30.2K ﹤0.01% 959
2018
Q4 		$11K Hold
133
– – ﹤0.01% 1204
2018
Q3 		$23K Buy
133
+128
+2,560% +$19.3K ﹤0.01% 957
2018
Q2 		$1K Sell
5
-9
-64% -$1K ﹤0.01% 1457
2018
Q1 		$1K Buy
+14
New +$1.39K ﹤0.01% 1281

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

CAPTRUST Financial Advisors's LGND Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Ligand Pharmaceuticals (LGND) stake by 105% in Q1 2026, buying an estimated $3.03M and bringing the position to 29,900 shares worth $5.97M. The position accounts for 0.01% of the portfolio, ranked #700.

CAPTRUST Financial Advisors first reported a position in LGND in Q1 2018 and has held it in 28 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • CAPTRUST Financial Advisors held 29,900 shares of Ligand Pharmaceuticals worth $5.97M as of Q1 2026.
  • CAPTRUST Financial Advisors bought 15,321 Ligand Pharmaceuticals shares in Q1 2026, an estimated $3.03M.
  • Ligand Pharmaceuticals made up 0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #700 holding.
  • CAPTRUST Financial Advisors first reported a position in Ligand Pharmaceuticals in Q1 2018 and has held it in 28 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.